Bracket Announces the Addition of SMS Messaging to the Bracket RTSM Platform
WAYNE, Pa., Dec. 14, 2015 /PRNewswire/ -- Bracket, a leading clinical trial specialty services provider, announced this week an important new update to its Randomization and Trial Supply Management product. Mobile patient reminders, delivered via SMS text messaging, are now available as a core component of Bracket's RTSM 4.0 platform.
"Medication and diary compliance is an essential step to executing a successful clinical trial. Expanding the tools available in our platform to ensure patients are taking their medications and reporting their symptoms is another step in our continuing commitment to improving the communication tools available in our eClinical suite," stated Jim Primerano, GM, eClinical, at Bracket.
Bracket SMS allows for reminders to be sent direct to patient mobile phones when they've opted in to the service. Patient information is encrypted and stored safely, and both patients and investigators can opt out of the service at any time. SMS is available globally to any study utilizing Bracket RTSM.
"Investigators and Clinical Trial sites need the right tools to execute research with their patients. Helping them improve medication compliance is one additional feature we include in our platform to help in this mission," stated Jeff Kinell, CEO of Bracket.
About Bracket
Bracket, with seven offices and more than 500 employees worldwide, is a specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at https://www.bracketglobal.com/
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
